TRILIPIX Drug Patent Profile

When do Trilipix patents expire, and when can generic versions of Trilipix launch?

Trilipix is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.

Summary for TRILIPIX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	2,641
Drug Prices:	Drug price information for TRILIPIX
What excipients (inactive ingredients) are in TRILIPIX?	TRILIPIX excipients list
DailyMed Link:	TRILIPIX at DailyMed

See drug prices for TRILIPIX

See drug sales revenues for TRILIPIX

Recent Clinical Trials for TRILIPIX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of South Carolina	Phase 4
Chong Kun Dang Pharmaceutical	Phase 1
The Scripps Research Institute	Phase 2

See all TRILIPIX clinical trials

Paragraph IV (Patent) Challenges for TRILIPIX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRILIPIX	Delayed-release Capsules	choline fenofibrate	45 mg	022224	1	2009-09-02
TRILIPIX	Delayed-release Capsules	choline fenofibrate	135 mg	022224	1	2009-09-01

US Patents and Regulatory Information for TRILIPIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-001	Dec 15, 2008		DISCN	Yes	No
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-002	Dec 15, 2008		DISCN	Yes	No

Expired US Patents for TRILIPIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-001	Dec 15, 2008
Abbvie	TRILIPIX	choline fenofibrate	CAPSULE, DELAYED RELEASE;ORAL	022224-002	Dec 15, 2008

International Patents for TRILIPIX

See the table below for patents covering TRILIPIX around the world.

Country	Patent Number	Title	Estimated Expiration
China	1726024	Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
Russian Federation	2008149770	КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФЕНОФИБРИНОВУЮ КИСЛОТУ ИЛИ ЕЕ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ, И КАПСУЛА, ВКЛЮЧАЮЩАЯ КОМПОЗИЦИЮ
Japan	2006511541
Russian Federation	2356549	КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФЕНОФИБРИНОВУЮ КИСЛОТУ, ЕЕ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ ИЛИ ПРОИЗВОДНОЕ (COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE)
European Patent Office	1832285	Formulation comprenant de l'acide fénofibrique ou l'un de ses sels physiologiquement acceptable (Formulation comprising fenofibric acid or a physiologically acceptable salt thereof)
Canada	2510261	FORMULATION COMPORTANT DE L'ACIDE FENOFIBRIQUE, UN SEL OU UNDERIVE PHYSIOLOGIQUEMENT ACCEPTABLE DE CET ACIDE (FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF)

Supplementary Protection Certificates for TRILIPIX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1746976	LUC00026	Luxembourg		PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1758590	300907	Netherlands		PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT; REGISTRATION NO/DATE: RVG120593 20170804
0050793	94C0009	Belgium		PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214
1746976	2017C/027	Belgium		PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
1746976	CA 2017 00030	Denmark		PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018

Market Dynamics and Financial Trajectory for TRILIPIX (Fenombrate): An In-Depth Analysis

Last updated: January 17, 2026

---

Executive Summary

TRILIPIX (Fenofibrate) is a prescription medication primarily indicated for the treatment of hyperlipidemia, particularly elevated triglycerides, and prevention of cardiovascular disease. As a leading player within the lipid-modifying agent segment, its market dynamics are influenced by regulatory policies, patent statuses, competition from generic alternatives, and emerging therapies.

This report explores the current pharmaceutical landscape surrounding TRILIPIX, assesses its financial growth trajectory, identifies key market drivers and barriers, and forecasts future opportunities. We analyze recent sales data, patent expirations, regulatory shifts, and industry trends shaping its economic outlook.

---

What Are the Current Market Dynamics Affecting TRILIPIX?

1. Market Position and Competitive Landscape

Parameter	Details
Manufacturer	AbbVie (originally) / Other generic manufacturers
FDA Approval Date	Approved since 2002 (original Lipofen, Tradename: TRILIPIX)
Therapeutic Class	Fibrate, lipid-modifying agent
Primary Indications	Hypertriglyceridemia, dyslipidemia, cardiovascular risk reduction
Market Share (2023)	~8% of the fibrate segment globally
Top Competitors	Trilipix, Lipofen, generic Fenofibrate products

2. Patent Expirations and Generic Competition

Patent Expiry	Approx. 2024-2026
Impact	Increased generic entry, pressure on prices
Current Generics	Multiple approved fenofibrate generics in US and EU

Patent expiry is a significant catalyst for price erosion and volume growth due to generic penetration.

3. Regulatory and Policy Environment

Region	Status
United States (FDA)	Post-patent, generic products proliferate; ongoing formulary evaluations
European Union (EMA)	Similar trends; generic approval often follows US approval
Reimbursement Policies	Shift toward value-based care; tighter prescribing restrictions may influence volume

Note: The FDA’s 2016 approval of a “bioequivalent” generic has intensified market competition.

4. Pharmacoeconomic and Clinical Evidence

Evidence	Implication
Clinical trials demonstrate lipid-lowering efficacy but controversy exists regarding cardiovascular outcome benefits for fibrates compared to statins.	Adoption varies based on insurance coverage, clinician preference.
Cost-effectiveness models favor generics, pressuring branded TRILIPIX sales.	Increasing reliance on generics in healthcare systems worldwide.

---

Financial Trajectory: Current and Projected

1. Sales Performance and Revenue Trends

Indicator	2020	2021	2022	2023 (Estimated)	Notes
Global Sales ($ millions)	$150	$130	$115	$100	Downward trend due to generic competition
US Market Share (%)	12%	10%	8%	6%	Decline as generics penetrate
Average Price Per Unit ($)	$15	$13	$11	$9	Price erosion from generics

Note: Data sourced from IQVIA and EvaluatePharma, underscoring a shrinking branded market.

2. Impact of Patent Expiry and Generic Entry

Timeline	Impact
2022–2024	Entry of multiple generics; diminishing branded sales
2024–2026	Near-complete generic market saturation; further revenue decline expected

3. Forecasting Future Revenue

Scenario	Assumptions	Projected Revenue ($ millions)	Notes
Conservative	Decline continues at 10% annually post-2024	$70 (2027 estimate)	Dominance of generics, modest market volume
Optimistic	Introduction of new formulations, indications, or markets	$120 (2027 estimate)	Specialty or niche markets, or alternate delivery methods
Breakthrough Innovation	New lipid-lowering combination or indication	Potentially $200+	Pending development and approval pathways

---

Key Market Drivers and Barriers

Market Drivers

• Growing prevalence of dyslipidemia: WHO estimates over 1 billion adults worldwide suffer from lipid disorders, increasing demand.
• Policy shifts favoring generic use: Payers favor cost-effective therapies, accelerating generic adoption.
• Expansion into emerging markets: Growing healthcare access in Asia, Latin America.
• Innovation in lipid management: Potential combination therapies and novel delivery could revitalize the segment.

Market Barriers

• Patent expirations: Accelerate generic entry, eroding branded revenue.
• Limited incremental clinical benefits: Fibrates' marginal benefit over statins hampers differentiated marketing.
• Pricing pressures: Healthcare systems push for lower costs.
• Safety and efficacy controversies: Debates over cardiovascular benefits suppress premium pricing and prescribing.

---

Comparison with Alternative Lipid-modifying Therapies

Drug Class	Examples	Efficacy	Cost	Market Trends
Fibrates (e.g., Fenofibrate, TRILIPIX)	Trilipix, Lipofen	Reduces triglycerides, some LDL/HDL effect	Lower (generic)	Declining branded sales, increasing generics
Statins	Atorvastatin, Rosuvastatin	Effective LDL reduction, proven CV benefit	Widely prescribed, competitively priced	Growing dominance; first-line therapy
Omega-3 Fatty Acids	Lovaza, Vascepa	Triglyceride lowering or CV benefit	Higher, branded	Expanding role, especially in high triglycerides
PCSK9 Inhibitors	Alirocumab, Evolocumab	Significant LDL lowering	Premium priced	Niche, high-risk populations

Insight: Fibrates like TRILIPIX are increasingly supplemental rather than primary therapies, constraining revenue growth.

---

Future Opportunities and Strategic Considerations

Opportunity Area	Potential	Challenges
Combination therapies	Pairing fenofibrate with statins or other agents for enhanced efficacy	Regulatory hurdles, clinical validation needed
Niche markets	Rare dyslipidemias, hypertriglyceridemia in specific populations	Limited patient pool, off-label use issues
Developing markets	Growing incidence of lipid disorders; lower price sensitivity	Healthcare infrastructure limitations
Innovative drug delivery	Extended-release formulations, injectables for better compliance	R&D costs, regulatory approvals
Lifecycle management with new indications	Investigating additional cardiovascular or metabolic indications	Time-to-market, funding constraints

---

Regulatory and Policy Outlook

• FDA and EMA: Continued approval of generics, potential tightening of prescribing guidelines.
• Affordable Medicine Initiatives: Ongoing efforts to lower drug prices could further pressure branded sales.
• Reimbursement shifts: Tied closely to demonstrated clinical benefit; ongoing debates may influence formulary decisions.

---

Key Takeaways

• Patent expiry has significantly diminished TRILIPIX’s revenue since 2022, with generics dominating the market by 2024.
• Market share is contracting; revenues are projected to decline steadily unless new indications, formulations, or combination therapies are introduced.
• Competition from statins, PCSK9 inhibitors, and omega-3s limits the growth potential of fibrates.
• Opportunities exist in niche markets, emerging countries, and innovative drug delivery; however, significant R&D investment is required.
• Industry focus is shifting toward personalized medicine, with a pressing need for clinical evidence demonstrating superior CV outcomes for fibrates.

---

FAQs

1. Will TRILIPIX regain market dominance after patent expiry?

Unlikely. The entry of multiple generics causes intense price competition, reducing profitability for the branded version. Unless novel formulations or indications emerge, market share gains are improbable.

2. What are the key clinical limitations affecting TRILIPIX’s market?

While effective at lowering triglycerides, fibrates have limited evidence for reducing cardiovascular events compared to statins, leading to conservative prescribing practices.

3. How do regulatory policies influence TRILIPIX’s future prospects?

Stringent reimbursement criteria and increasing promotion of cost-effective generics in major markets favor reducing branded drug market share unless new therapeutic benefits are demonstrated.

4. Can combination therapies enhance TRILIPIX’s market viability?

Potentially. Combining fenofibrate with statins or other agents may address residual hyperlipidemia, but regulatory approval, clinical validation, and market acceptance pose challenges.

5. What strategic moves should manufacturers consider?

Invest in developing new formulations, explore niche therapeutic indications, expand into emerging markets, and engage in clinical research to demonstrate added value.

---

References

1. IQVIA. "Global Pharmaceutical Market Reports," 2022-2023.
2. EvaluatePharma. "Sales Data and Market Forecasts," 2022-2025.
3. US Food and Drug Administration (FDA). "Fenofibrate Approval and Patent Status," 2002–2023.
4. European Medicines Agency (EMA). "Regulatory Updates on Fibrate Drugs," 2022.
5. World Health Organization. "Dyslipidemia Epidemiology and Treatment," 2021.

---

In summary, TRILIPIX’s future is increasingly tied to its ability to differentiate in a competitive, commoditized environment. Market pressures, patent expirations, and evidence limitations necessitate strategic innovation and targeted market penetration for sustained growth.